RVMD
Revolution Medicines, Inc.
$186.99
-0.37%
2026-10-23
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Key Fundamentals
Forward P/E
-34.07
EPS (TTM)
$-8.87
ROE
-79.1%
Profit Margin
0.0%
Debt/Equity
45.68
Price/Book
27.35
Beta
1.41
Market Cap
$43.93B
Avg Volume (10D)
2.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$224.31
60D Low
$175.91
Avg Volume
2.0M
Latest Close
$186.99
Get breakout alerts for RVMD
Sign up for Breakout Scanner to receive daily notifications when RVMD triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Revolution Medicines, Inc. (RVMD) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors RVMD daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. RVMD operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.